Delving into the Latest Updates on Ethyl chloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ethyl chloride (USP), chloroethane, monochloroethane

Target-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication

Pain

Inactive Indication-

Originator Organization

New York University School of Medicine

Active Organization

New York University School of Medicine

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC2H5Cl

InChIKeyHRYZWHHZPQKTII-UHFFFAOYSA-N

CAS Registry75-00-3

A procedure frequently performed by orthopaedic providers is the administration of corticosteroid injections for the management of various soft tissues and joint-related conditions, such as osteoarthritis, tendinitis, carpal tunnel syndrome, trigger finger, and de Quervain's tenosynovitis. While these injections have demonstrated effectiveness in alleviating symptoms, the discomfort associated with the procedure can be a source of anxiety and apprehension for patients. This discomfort arises from the sensation of the needle entering the affected area and the burning sensation induced by the corticosteroid solution.

Start Date01 Nov 2024

Sponsor / Collaborator

The University of Chicago

NCT06596486 / Not yet recruitingNot ApplicableIIT

A Comparison of CoolStick and Ethyl Chloride Spray for the Assessment of Sensory Block to Light Touch and Cold Before Caesarean Section Under Spinal or Combined Spinal-epidural Anaesthesia

The main aim of this study is to compare CoolStick to ethyl chloride spray for the assessment of light touch following neuraxial anaesthesia for caesarean delivery.
Coolstick and ethyl chloride will also be compared for the assessment of cold sensation.
Participants will also be asked whether they experienced any intraoperative pain.

Start Date01 Nov 2024

Sponsor / Collaborator

Barts & The London NHS Trust

CTRI/2024/07/070481 / Not yet recruitingPhase 2/3IIT

A Randomised Study to Compare the Effectiveness of One Spray versus Two Sprays of Ethyl Chloride of Reducing Venepuncture Induced Pain in Patients requiring IV Cannulation Before Surgery under Anaesthesia at SMS Medical College, Jaipur - Nil

Start Date31 Jul 2024

Sponsor / Collaborator-

100 Clinical Results associated with Ethyl chloride

Login to view more data

100 Translational Medicine associated with Ethyl chloride

Login to view more data

100 Patents (Medical) associated with Ethyl chloride

Login to view more data

589

Literatures (Medical) associated with Ethyl chloride

01 Dec 2024·Biochemical and Biophysical Research Communications

Ethyl gallate ameliorates diabetes-induced Alzheimer's disease-like phenotype in rats via activation of α7 nicotinic receptors and mitigation of oxidative stress

Article

Author: Nagori, Kushagra ; Nakhate, Kartik T. ; Pradhan, Madhulika ; Nakhate, Kartik T

Cognitive decline, an important comorbidity of type 2 diabetes (T2D), is attributed to oxidative stress and impaired cholinergic signaling in the brain. The α7 nicotinic acetylcholine receptor (α7nAChR) is densely distributed in the hippocampus and cortex, and exerts neuroprotective and procognitive actions. Ethyl gallate (EG), a natural phenolic antioxidant compound, showed high in-silico binding affinity towards α7nAChR and brain penetrability. Therefore, the present study aimed to evaluate the involvement of α7nAChR in the potential of EG to ameliorate T2D-induced Alzheimer's disease-like condition. T2D was induced by intraperitoneal (i.p.) injection of streptozotocin (35 mg/kg) in rats on high-fat diet. Diabetic animals were treated with EG (10 and 20 mg/kg, i.p.) for four weeks, and their learning and memory performance was evaluated by the Morris water maze (MWM). Further, the brains were subjected to biochemical analysis of antioxidants like glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT), and oxidative stress marker malonaldehyde (MDA). While diabetic rats showed a significant decline in cognitive performance in the MWM, a substantial improvement was noticed following EG treatment. Further, the diabetes-associated reductions in GSH, SOD, and CAT levels, along with increased MDA contents in the brain, were effectively restored by EG. Interestingly, pre-treatment with α7nAChR antagonist methyllycaconitine (1 mg/kg, i.p.) attenuated the effects of EG on behavioral and biochemical parameters. The results suggest that EG may augment cholinergic signaling in the brain via α7nAChR to mitigate oxidative stress, consequently alleviating T2D-associated dementia. Therefore, EG could be a potential candidate for addressing cognitive impairment comorbid with T2D.

01 Dec 2024·European Journal of Pharmaceutical Sciences

Evaluation of polymer combinations in vaginal mucoadhesive tablets for the extended release of acyclovir

Article

Author: Martín-Bartolomé, Laura ; Ruiz-Caro, Roberto ; Notario-Pérez, Fernando ; Veiga, María Dolores

Genital herpes, caused by herpes simplex virus type 2 (HSV-2), affects nearly 500 million people, mostly women. Since the main route of transmission is sexual contact, the development of an acyclovir extended-release vaginal microbicide would be a suitable tool for the prevention of virus transmission. In this work, we evaluated the potential of three polymers with different characteristics (chitosan, xanthan gum and ethyl cellulose) for obtaining acyclovir extended-release vaginal tablets. By combining the polymers, certain useful synergies were observed to modify their mucoadhesive capacity and control drug release. In the swelling studies, it observed that a polyelectrolyte complex with more moderate swelling and sustained gelation was formed between chitosan and xanthan gum exclusively in acidic medium (simulated vaginal fluid). This complex allowed prolonging the mucoadhesion of the tablets in ex vivo studies performed with vaginal mucosa, which would translate into better retention in the vagina after administration. In addition, the combination of chitosan and xanthan gum allowed obtaining a controlled release of acyclovir for 5 days, regardless of the pH of the medium, which would guarantee that drug release continues even in the presence of seminal fluid.

01 Nov 2024·International Journal of Pharmaceutics

Fabrication of osmotic pump tablets utilizing semisolid extrusion three-dimensional printing technology

Article

Author: Wang, Xiangyu ; Pan, Hao ; Gong, Ye ; Ji, Yang ; Fang, Dongyang ; Chen, Hao

The utilization of three-dimensional (3D) printing technology is prevalent in the fabrication of oral sustained release preparations; however, there is a lack of research on 3D-printed osmotic pump tablets. A 3D-printed core-shell structure bezafibrate osmotic pump tablet was developed based on the characteristics of rapid absorption and short half-life of bezafibrate, utilizing semisolid extrusion (SSE) 3D printing technology. First, the properties of different shell materials were investigated to define the composition of the shell, and ultimately, the optimal formulation was found to be ethyl cellulose:cellulose acetate:polyethylene glycol = 2:1:2. The formulation of the tablet core was defined based on the printing performance and release behavior. The formulation consisted of bezafibrate, lactis anhydrous, sodium bicarbonate, sodium alginate, polyethylene oxide and sodium dodecyl sulfate at a ratio of 400:400:300:80:50:50. The tablet was capable of achieving zero-order release. The physicochemical properties were also characterized. The pharmacokinetic data analysis indicated that there were no statistically significant differences in the pharmacokinetic parameters between the 3D-printed tablets and the reference listed drugs. There was a strong correlation between the in vitro and in vivo results for the 3D-printed tablets. The results showed that SSE printing is a practical approach for manufacturing osmotic pump tablets.

100 Deals associated with Ethyl chloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04088	-	-	DB13259

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 1	-	New York University School of Medicine	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02587143 (CTgov)	Not Applicable	Pain \| Anesthesia	126	Alcohol (Control)	rmyuhuemfk(nttqoibbzh) = imvwbhbnqs iruadpcbcs (dslvopoams, kqqtajjdzb - msarrpymqi) View more	-	22 Jan 2020
				Ethyl chloride (Ethyl Chloride)	rmyuhuemfk(nttqoibbzh) = grkxhrwfwy iruadpcbcs (dslvopoams, zdyxfloado - zdjmmnxljq) View more
NCT03054740 (CTgov)	Phase 4	Pain	30	Gebauer Ethyl Chloride (Gebauer Ethyl Chloride)	vzczslwjww(xypphoadzd) = mqmcgadnkd plavrbngar (qyfiankqnz, pgwozqmgvo - ylxapkubtd) View more	-	03 Oct 2018
				Nature's Tears (Nature's Tears)	vzczslwjww(xypphoadzd) = mphirvbtir plavrbngar (qyfiankqnz, wudkricvno - pfkxseztrv) View more
NCT02592629 (CTgov)	Phase 4	Shoulder Pain	19	lidocaine+Kenalog (no Topical or Subcutaneous Anesthetic)	qnplnynuak(hnsdkmaecm) = npghmrsgjk vucldenxeu (fvdytvcpiq, zxtqzqmqjk - xzfuezhfha) View more	-	10 Sep 2018
				lidocaine+Kenalog (Subcutaneous Lidocaine)	qnplnynuak(hnsdkmaecm) = uwhfokwfue vucldenxeu (fvdytvcpiq, zdgnnichqt - gcxoeioxpk) View more